98%
921
2 minutes
20
Carbohydrate antigen 19-9 (CA19-9) is a clinically established biomarker primarily used for monitoring disease progression and recurrence in pancreatic and gastrointestinal cancers. Accurate and continuous quantification of CA19-9 in patient samples is critical for effective clinical management. This study aimed to develop dual-emitting molecularly imprinted nanopolymers (dual@nanoMIPs) for ratiometric and reliable detection of CA19-9 in serum. Dual-emitting nanoMIPs were synthesized via a one-step molecular imprinting process, incorporating both blue-emitting carbon dots (b-CDs) as internal reference fluorophores and yellow-emitting quantum dots (y-QDs) as responsive probes. The CA19-9 template was embedded into the polymer matrix to create specific recognition sites. Fluorescence measurements were carried out under 365 nm excitation in 1% human serum diluted in phosphate-buffered saline (PBS). : The dual@nanoMIPs exhibited a ratiometric fluorescence response upon CA19-9 binding, characterized by the emission quenching of the y-QDs at 575 nm, while the b-CDs emission remained stable at 467 nm. The fluorescence shift observed in the RGB coordinates from yellow to green in the concentration range of CA19-9 tested, improved quantification accuracy by compensating for matrix effects in serum. A linear detection range was achieved from 4.98 × 10 to 8.39 × 10 U mL in serum samples, with high specificity and reproducibility. The dual@nanoMIPs developed in this work enable a stable, sensitive, and specific detection of CA19-9 in minimally processed serum, offering a promising tool for longitudinal monitoring of cancer patients. Its ratiometric fluorescence design enhances reliability, supporting clinical decision-making in the follow-up of pancreatic cancer.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12292350 | PMC |
http://dx.doi.org/10.3390/biomedicines13071629 | DOI Listing |
Background: The accuracy of CA19-9 detection results is very important for the early detection and treatment of pancreatic cancer, cholangiocarcinoma and other malignant tumors. At present, endogenous substances such as heterophilic antibodies will cause interference in the commonly used detection method is electrochemilumines-cence immunoassay, resulting in inaccurate results and affecting clinical diagnosis and treatment.
Methods: This paper reports a patient with an abnormal increase in serum CA19-9 level to explore how to accurately identify non-specific interference and anti-interference countermeasures.
Surgery
September 2025
Division of Visceral Surgery, Department of General Surgery, Medical University of Vienna, Vienna, Austria; Department of Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, MA; Department of General, Visceral and Transplantation Surgery, Heidelberg University Hospital, Heide
Introduction: Very early recurrence in pancreatic ductal adenocarcinoma has been defined as recurrence ≤3 months after resection. Besides others, neoadjuvant treatment is delivered based on the assumption of preoperative eradication of micrometastasis as well as local downstaging. Prognostic factors of very early recurrence after neoadjuvant treatment remain largely unexplored.
View Article and Find Full Text PDFMed Oncol
September 2025
Chemistry Department, Faculty of Science, Cairo University, Cairo, Egypt.
Pancreatic cancer is among the most lethal forms of cancer, with a five-year survival rate under 7%, primarily due to its late clinical presentation and rapid disease progression. Although the oncogenic development of pancreatic tumors can span over a decade, early diagnosis remains a major clinical challenge, as current diagnostic approaches-including imaging modalities and blood-based markers like CA19-9-lack the requisite sensitivity for detecting early-stage disease. Liquid biopsy has emerged as a promising, non-invasive diagnostic technique by enabling the detection of circulating tumor-specific nucleic acids, particularly circulating tumor DNA (ctDNA) and microRNAs (miRNAs).
View Article and Find Full Text PDFFront Oncol
August 2025
Department of Digestive Surgery, Xijing Hospital of Digestive Diseases, Fourth Military Medical University, Xi'an, Shaanxi, China.
Background: Patients with metachronous liver metastasis (MLM) in gastric cancer generally have a poor prognosis. Early detection and accurate prediction of MLM are crucial for improving clinical outcomes. This study aims to identify the risk factors for MLM through clinical pathological parameters and develop a predictive model for MLM in gastric cancer.
View Article and Find Full Text PDFBr J Cancer
September 2025
Clinical Genomics and Therapeutics Division, Translational Genomics Research Institute, Part of City of Hope, Phoenix, AZ, USA.
Background: Lack of reliable biomarkers for early detection and monitoring contributes to the poor prognosis of pancreatic ductal adenocarcinoma (PDAC), as the current clinical marker, CA19-9, lacks adequate specificity and sensitivity.
Methods: Serum concentrations of ALPPL2-positive and THBS2-positive exosomes were measured using an ExoView assay in two cohorts: a cohort of 219 subjects, including non-disease controls and patients with early- or late-stage PDAC, and a longitudinal cohort of 26 patients with advanced PDAC undergoing treatment.
Results: Exosomal ALPPL2 and THBS2 distinguished non-cancer cases from PDAC with high accuracy; area under the curve (AUC) values = 0.